Compare SLAI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
Current Price
| Metric | SLAI | IMNN |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 12.5M |
| IPO Year | N/A | 2000 |
| Metric | SLAI | IMNN |
|---|---|---|
| Price | $0.84 | $3.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 86.6K | 29.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.37 |
| 52 Week High | $2.55 | $9.32 |
| Indicator | SLAI | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 60.75 |
| Support Level | $0.81 | $3.53 |
| Resistance Level | $1.31 | $3.62 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 70.81 | 92.45 |
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).